Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
PHILADELPHIA, May 10, 2013 — /PRNewswire/ -- Echo Therapeutics, Inc. (Nasdaq: ECTE), a company developing its needle-free Symphony® CGM System as a non-invasive, wireless, transdermal continuous glucose monitoring system, today announced financial results for the quarter ended March 31, 2013. Echo’s Quarterly Report on Form 10-Q, as filed with the SEC, will be available by visiting the Investors section of Echo’s website at www.echotx.com.
Help employers find you! Check out all the jobs and post your resume.
